About Lu Yang
- Growing evidence points to a link between inflammation and the initiation of prostate cancer. It is also linked to the progression of prostate cancer to being resistant to treatment.
- Dr. Yang and his team will conduct four Phase 1 clinical studies to investigate the effects of anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs), like aspirin, on prostate tumor initiation and progression.
- His team will also outline the precise molecular mechanism behind the effects of anti-inflammatory agents on preventing disease progression.
What this means to patients: The use of non-steroidal, anti-inflamatory drugs may provide a new treatment to prevent prostate cancer initiation and progression.
2013 PCF China Young Investigator in Honor of Stanley Zax
Lu Yang, MD
West China Hospital, Sichuan University
Qiang Wei, MD and Tianyong Fan, MD
Treating inflammation to prevent prostate cancer initiation and progression.